HEALTH REPORT
Until about age 30, we make more bone than we lose, and the body naturally produces enough collagen to cushion joints from rubbing against each other. After 40, we lose about one percent of bone mass per year and collagen levels decrease, causing joint pain, inflammation and impaired movement. The good news? There is a remarkable new supplement to treat and even reverse joint problems. A new frontier Next-Gen Joint Relief Breaking news: there is a new and exciting supplement to support joint health, improve mobility and reduce pain.
In the evolving landscape of nutritional science and joint health support, UC-II ® undenatured type II collagen has emerged as the next generation joint health ingredient with compelling clinical backing. As the population is ageing and the prevalence of joint-related discomfort increases, not just among older adults but also among younger, physically active individuals, there is growing interest in effective natural solutions. UC-II ® undenatured type II collagen is an innovative approach, working through a novel immunological mechanism rather than
This process reduces joint inflammation and facilitates cartilage repair. In contrast, denatured type II collagen does not possess these critical structural elements. Put simply, UC-II ® modulates the immune system’s response to type II collagen found in joint cartilage, thereby reducing inflammatory responses that cause cartilage degradation and joint discomfort. Clinical proof A multitude of clinical studies support the effectiveness of UC-II ® and show that UC-II ® has:
After 40, we lose about one percent of bone mass per year and collagen levels decrease, causing joint pain, inflammation and impaired movement
simply acting as a ‘building block’, like traditional collagen supplements. Unlike hydrolysed or denatured collagen, which is broken down into peptides and amino acids during processing, UC-II ® retains its native (undenatured) triple helix structure. This structure enables it to interact with the gut-associated lymphoid tissue (GALT), triggering a process known as oral tolerance. Upon ingestion, UC-II ® undenatured type II collagen is thought to convert naive T-cells (mature T-cells that has not yet been activated) into T regulatory immune cells that specifically identify type II collagen. These T regulatory cells then travel through the bloodstream and, upon encountering type II collagen in joint cartilage, they release anti-inflammatory substances (cytokines), such as transforming growth factor-beta (TGF-beta) and interleukins.
• improved joint function, mobility, and flexibility; • increased range of motion in knee flexion and extension; • reduced pain during standing upright and going up or down stairs; • decreased discomfort in climbing ascending stairs; • decreased discomfort in bending to floor to pick an object; and • decreased discomfort in squatting during physical activity. A multicentre, randomised, double-blind, placebo-controlled study found that, after 24 weeks, there was a statistically significant increase in knee range of motion flexion found in the UC-II ® group versus the placebo group. In addition, there was an increase in knee range of motion extension over time in the UC-II ® group. A randomised trial investigated the effect of UC-II ®
6
ISSUE 74 • 2025
Made with FlippingBook Learn more on our blog